Bitcoin briefly fell below $74,000 on Nov. 8 as over $1 billion in leveraged crypto positions were forcibly closed ahead of upcoming U.S. inflation data. It later recovered above $75,000. Over five U.S. trading sessions ending Nov. 6, Bitcoin ETFs saw a net outflow of $1.28 billion, with BlackRock's iShares Bitcoin Trust experiencing $1.21 billion in withdrawals. The October Consumer Price Index (CPI) report, due Nov. 10, is expected to influence market movements further.
Bitcoin's recent price volatility provides context for Pluang's cryptocurrency market snapshot as of Nov 09, 2026 12:41 WIB: Among 50 major cryptocurrencies priced on Pluang, 7 rose and 42 fell today. Notable movers include ALGO (Algorand) at Rp1.656 with a 1-day change of -3.55% and a Pluang order activity split of 73% Sell / 27% Buy, SAND (The Sandbox) at Rp745 with a -3.51% change and 68% Sell / 32% Buy activity, and KSM (Kusama) at Rp56.224 down 3.40%, with a typical hold time on Pluang of 81 days.
US President Donald Trump defended his family's cryptocurrency business, World Liberty Financial, stating he has no involvement in its operations and cannot stop his sons from running it while he is in office. The company faces scrutiny over a $500 m...
XRP has sharply declined against Bitcoin, losing nearly 8% of its value over the past week amid a broader cryptocurrency market downturn. The coin dropped 4.9% in the last 24 hours and is currently priced around $1.10. This decline is more severe tha...
Dapirolizumab pegol (DZP), an investigational biologic for systemic lupus erythematosus (SLE), demonstrated greater treatment response rates compared to placebo when combined with standard care in the Phase 3 PHOENYCS GO trial. Using a novel Treatmen...
argenx will acquire Unnatural Products (UNP) for $550 million upfront plus up to $600 million in milestones, totaling about $1.15 billion. UNP specializes in orally-delivered macrocyclic peptides targeting previously undruggable diseases, enhancing a...
Valneva announced positive Phase 2 trial results for its tetravalent Shigella vaccine candidate S4V2, showing a favorable safety profile and encouraging immune responses in infants and adults. The infant trial in Kenya demonstrated significant antibo...
